Lexeo Therapeutics Stock Rated “Buy” by Chardan Capital with $17 Target

Lexeo Therapeutics (NASDAQ: LXEO) received a “buy” rating from Chardan Capital, reaffirming its positive outlook on the stock in a report released on October 17, 2023. The firm has set a price target of $17.00, indicating a potential upside of 109.36% from the stock’s current trading levels.

Several other investment firms have also weighed in on Lexeo Therapeutics recently. On October 8, Weiss Ratings reiterated a “sell (d-)” rating, while Oppenheimer restated an “outperform” rating, setting the price target at $20.00. HC Wainwright revised their price objective down from $13.00 to $10.00 but maintained a “buy” rating. Cantor Fitzgerald initiated coverage with an “overweight” rating and a $19.00 target price. Additionally, Leerink Partners raised their target from $9.00 to $20.00 with an “outperform” rating.

Currently, one analyst has issued a Strong Buy rating for Lexeo Therapeutics, eight have given it a Buy rating, and one analyst has rated it as a Sell. According to data from MarketBeat, the stock holds a consensus rating of “Moderate Buy” with a consensus price target of $19.00.

Recent Earnings and Insider Activity

Lexeo Therapeutics reported its quarterly earnings on November 5, 2023. The company posted an earnings per share (EPS) of ($0.33), which surpassed analysts’ expectations of ($0.48) by $0.15. Analysts predict that Lexeo will post an EPS of ($3.14) for the current fiscal year.

Insider trading activity has also been notable. On October 17, CEO Richard Nolan Townsend sold 13,133 shares at an average price of $8.94, totaling approximately $117,409.02. This transaction reduced his holdings to 242,118 shares, valued at roughly $2,164,534.92, reflecting a 5.15% decrease in ownership. Another insider, Tai Sandi See, sold 3,888 shares for around $34,758.72, resulting in a 5.57% decrease in their ownership.

Over the last 90 days, insiders have sold a total of 24,646 shares valued at $221,037, with corporate insiders holding 5.30% of the stock.

Institutional Investments and Company Overview

Institutional trading has been active as well. Vanguard Personalized Indexing Management LLC increased its stake in Lexeo Therapeutics by 10.6% in the third quarter, now owning 16,595 shares valued at $110,000. Bank of America Corp DE also boosted its stake by 6.1%, acquiring an additional 1,626 shares and bringing its total to 28,279 shares valued at $188,000.

Intech Investment Management LLC raised its holdings by 20.7% during the second quarter, now owning 13,682 shares worth $55,000. Other firms, such as AXQ Capital LP and China Universal Asset Management Co. Ltd., have also increased their positions, with institutional investors now owning 60.67% of Lexeo Therapeutics.

Lexeo Therapeutics, based in the United States, is a clinical-stage biotechnology company focused on developing innovative therapies for central nervous system disorders. It aims to create precision-designed treatments for mental health conditions, including anxiety and depression, by leveraging advanced medicinal chemistry. The company’s pipeline includes proprietary synthetic molecules that target specific neural pathways, enhancing safety and tolerability compared to traditional treatments.